In this study, NfL blood serum concentrations were measured by using a single-molecule array immunoassay protocol in patients carrying AD autosomal-dominant mutations in genes encoding APP, PSEN1, and/or PSEN2 proteins and compared to control individuals, showing elevated levels around 6 years preceding AD symptoms onset (Table 2) [19]. This evidence concerns the gene APP and Alzheimer disease.